PROCEPT BioRobotics Corporation announced on October 29, 2024, the pricing of its underwritten public offering of 1,923,076 shares of common stock at $91.00 per share. This offering is expected to generate aggregate gross proceeds of approximately $175 million for the company.
The offering is anticipated to close on or about October 31, 2024, subject to customary closing conditions. BofA Securities, Piper Sandler, and Morgan Stanley are serving as joint book-running managers for the transaction.
A selling stockholder also granted the underwriters a 30-day option to purchase up to an additional 288,461 shares of common stock at the public offering price. PROCEPT BioRobotics will not receive any proceeds from the sale of shares by this selling stockholder.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.